在中风中考虑饮食中的生物活性化合物/后生物,食物和方法
1School of Nutrition and Food Science, Louisiana State University Agricultural Center Ringgold Standard Institution, Baton Rouge, LA, USA.
Nutritional neuroscience
|October 28, 2025
概括
饮食干预可以通过准肠道失调和炎症来预防二次中风. 富含生物活性化合物的植物性饮食可以恢复肠道健康并改善中风后的神经缺陷.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 营养科学 营养科学
背景情况:
- 肠道失调与中风有关,影响免疫反应和血脑屏障的完整性.
- 双向肠-大脑相互作用在中风后恢复和炎症中发挥着关键作用.
研究的目的:
- 审查二次中风预防的饮食干预措施.
- 探索肠道失生症在中风发展中的机制及其对免疫系统的影响.
主要方法:
- 研究了中风后的线粒体功能障碍,巨细胞脱粒化和肠道微生物群变化.
- 分析了方法的营养基因组影响,并比较了地中海,冲绳和北欧饮食.
- 评估免疫介导的炎症反应和屏障功能变化.
主要成果:
- 新出现的证据将中风前和中风诱导的肠道失调联系在一起.
- 建议的中风后饮食中含有生物活性化合物,以恢复肠道活化和改善缺陷.
- 饮食干预可以减轻炎症和免疫损伤.
结论:
- 针对肠道微生物群的饮食干预措施对于二次中风预防至关重要.
- 个性化的中风后饮食,包括植物性食品和特定的方法,显示出有前途.
- 需要进一步的临床试验来优化中风患者的饮食策略.
相关概念视频
Atherosclerosis IV: Nursing Management
361
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
361
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
193
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
193
Bioavailability: Influencing Factors
331
Bioavailability refers to the extent and rate at which a drug reaches systemic circulation in its active form. Extent refers to the amount of the drug that makes it into circulation, while rate is the speed at which it enters circulation. It is influenced by several factors critical for optimizing drug formulations, dosing regimens, and therapeutic outcomes.Physicochemical properties of drugs and formulationsThe solubility, stability, and dissolution rate of a drug significantly impact its...
331
Factors Affecting Drug Biotransformation: Biological
513
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
513


